BRPI0418623A - composição farmacêutica, e, embalagem - Google Patents
composição farmacêutica, e, embalagemInfo
- Publication number
- BRPI0418623A BRPI0418623A BRPI0418623-0A BRPI0418623A BRPI0418623A BR PI0418623 A BRPI0418623 A BR PI0418623A BR PI0418623 A BRPI0418623 A BR PI0418623A BR PI0418623 A BRPI0418623 A BR PI0418623A
- Authority
- BR
- Brazil
- Prior art keywords
- compositions
- packaging
- pharmaceutical composition
- vaginitis
- bioadhesive
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 3
- 238000004806 packaging method and process Methods 0.000 title abstract 2
- 206010046914 Vaginal infection Diseases 0.000 abstract 3
- 239000000203 mixture Substances 0.000 abstract 3
- 201000008100 Vaginitis Diseases 0.000 abstract 2
- 239000013543 active substance Substances 0.000 abstract 2
- 239000000227 bioadhesive Substances 0.000 abstract 2
- BLSQLHNBWJLIBQ-OZXSUGGESA-N (2R,4S)-terconazole Chemical compound C1CN(C(C)C)CCN1C(C=C1)=CC=C1OC[C@@H]1O[C@@](CN2N=CN=C2)(C=2C(=CC(Cl)=CC=2)Cl)OC1 BLSQLHNBWJLIBQ-OZXSUGGESA-N 0.000 abstract 1
- 241000222120 Candida <Saccharomycetales> Species 0.000 abstract 1
- 241000222122 Candida albicans Species 0.000 abstract 1
- HJLSLZFTEKNLFI-UHFFFAOYSA-N Tinidazole Chemical compound CCS(=O)(=O)CCN1C(C)=NC=C1[N+]([O-])=O HJLSLZFTEKNLFI-UHFFFAOYSA-N 0.000 abstract 1
- 239000003242 anti bacterial agent Substances 0.000 abstract 1
- 230000000843 anti-fungal effect Effects 0.000 abstract 1
- 230000000842 anti-protozoal effect Effects 0.000 abstract 1
- 239000003429 antifungal agent Substances 0.000 abstract 1
- 229940121375 antifungal agent Drugs 0.000 abstract 1
- 239000003904 antiprotozoal agent Substances 0.000 abstract 1
- 229940095731 candida albicans Drugs 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 230000003232 mucoadhesive effect Effects 0.000 abstract 1
- 210000004877 mucosa Anatomy 0.000 abstract 1
- 230000002035 prolonged effect Effects 0.000 abstract 1
- 229960000580 terconazole Drugs 0.000 abstract 1
- 229960005053 tinidazole Drugs 0.000 abstract 1
- 238000011200 topical administration Methods 0.000 abstract 1
- -1 triazole compound Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4168—1,3-Diazoles having a nitrogen attached in position 2, e.g. clonidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4166—1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4174—Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4196—1,2,4-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
- A61K9/0036—Devices retained in the vagina or cervix for a prolonged period, e.g. intravaginal rings, medicated tampons, medicated diaphragms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Reproductive Health (AREA)
- Gynecology & Obstetrics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Urology & Nephrology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Communicable Diseases (AREA)
- Endocrinology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
COMPOSIçãO FARMACêUTICA, E, EMBALAGEM. A invenção fornece composições farmacéuticas para a administração tópica no tratamento de infecções vaginais, por exemplo, vaginite. Tais composições compreendem: W pelo menos um composto de triazol ativo contra Candida albicans, preferivelmente pelo menos um tal composto que é adicionalmente ativo contra uma ou mais espécies de Candida que não a albicans, e (ii) pelo menos um medicamento anti-vaginite adicional, preferivelmente um agente antifúngico, antiprotozoário e/ou antibacteriano. As composições preferidas incluem como agentes ativos o terconazol em combinação com tinidazol e/ou tioconazol. Em um outro aspecto as composições de acordo com a invenção também incluem um agente bioadesivo, por exemplo, um mucoadesivo, para promover a adesão à mucosa vaginal. O uso de um bioadesivo também pode fornecer a liberação controlada, por exemplo, rápida e/ou demorada (prolongada), dos agentes ativos.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0405406.0A GB0405406D0 (en) | 2004-03-10 | 2004-03-10 | Anti-vaginitis compositions |
| PCT/GB2004/003972 WO2005087270A1 (en) | 2004-03-10 | 2004-09-17 | Anti-vaginitis compositions comprising a triazole |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BRPI0418623A true BRPI0418623A (pt) | 2007-05-29 |
Family
ID=32117416
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0418623-0A BRPI0418623A (pt) | 2004-03-10 | 2004-09-17 | composição farmacêutica, e, embalagem |
Country Status (7)
| Country | Link |
|---|---|
| CN (1) | CN1960763A (pt) |
| BR (1) | BRPI0418623A (pt) |
| EA (1) | EA011952B1 (pt) |
| GB (1) | GB0405406D0 (pt) |
| PL (1) | PL380815A1 (pt) |
| TR (1) | TR200606411T1 (pt) |
| WO (1) | WO2005087270A1 (pt) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4167964A4 (en) * | 2020-06-18 | 2024-07-17 | National Medical Supply, LLC | Vaginal gel |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20060140990A1 (en) * | 2003-09-19 | 2006-06-29 | Drugtech Corporation | Composition for topical treatment of mixed vaginal infections |
| AU2004274000B2 (en) | 2003-09-19 | 2009-07-30 | Drugtech Corporation | Pharmaceutical delivery system |
| MX2008001687A (es) * | 2005-08-12 | 2008-02-19 | Drugtech Corp | Composiciones de estrogenos y metodos terapeuticos de uso. |
| KR20080083190A (ko) * | 2006-01-05 | 2008-09-16 | 드러그테크 코포레이션 | 외음질 표면에 생체접착을 위한 약물 전달 시스템 |
| EA200870153A1 (ru) * | 2006-01-05 | 2008-12-30 | Драгтек Корпорейшн | Композиция и способ ее использования |
| US9211286B2 (en) * | 2006-09-12 | 2015-12-15 | Curatek Pharmaceuticals Holding, Inc. | Terconazole composition and method |
| US10758630B2 (en) | 2010-08-13 | 2020-09-01 | The Johns Hopkins University | Topical compositions and methods of detection and treatment |
| CN102091097B (zh) * | 2011-01-28 | 2013-04-03 | 武汉耦合医学科技有限责任公司 | 一种免冲洗产妇会阴医疗护理凝胶及其制备方法 |
| IT1403661B1 (it) | 2011-01-28 | 2013-10-31 | Probiotical Spa | Composizione effervescente in forma solida per uso in applicazioni vaginali per il trattamento di infezioni vaginali. |
| ITMI20110791A1 (it) | 2011-05-09 | 2012-11-10 | Probiotical Spa | Ceppi di batteri in grado di metabolizzare gli ossalati. |
| ITMI20110792A1 (it) | 2011-05-09 | 2012-11-10 | Probiotical Spa | Ceppi di batteri appartenenti al genere bifidobacterium per uso nel trattamento della ipercolesterolemia. |
| ITMI20111718A1 (it) | 2011-09-23 | 2013-03-24 | Probiotical Spa | Un materiale impermeabile alla umidita e allo ossigeno per confezionare prodotti dietetici, cosmetici e specialita medicinali. |
| WO2014027006A1 (en) | 2012-08-13 | 2014-02-20 | Edko Pazarlama Tanitim Ticaret Limited Sirketi | Bioadhesive formulations for use in drug delivery |
| WO2014026707A1 (en) | 2012-08-13 | 2014-02-20 | Edko Pazarlama Tanitim Ticaret Limited Sirketi | Anti-vaginitis compositions with improved release and adherence |
| ITMI20130793A1 (it) | 2013-05-14 | 2014-11-15 | Probiotical Spa | Composizione comprendente batteri lattici per uso nel trattamento preventivo e/o curativo delle cistiti ricorrenti. |
| EP3013368A1 (en) * | 2013-06-25 | 2016-05-04 | Mission Pharmacal Company | Novel formulations for the treatment of vaginal disorders |
| CN108235682A (zh) | 2015-09-29 | 2018-06-29 | 金伯利-克拉克环球有限公司 | 用于维护微生物群落的健康平衡的协同组合物 |
| ITUA20162013A1 (it) | 2016-03-24 | 2017-09-24 | Probiotical Spa | Composizione a base di batteri lattici per il trattamento contemporaneo di infezioni vaginali di origine micotica e batterica. |
| KR102769558B1 (ko) | 2017-02-28 | 2025-02-19 | 킴벌리-클라크 월드와이드, 인크. | 미생물총의 건강한 균형을 유지하기 위한 상승적 조성물 |
| EP4096655A4 (en) * | 2020-01-31 | 2024-02-28 | Exeltis Ilac Sanayii ve Ticaret Anonim Sirketi | PHARMACEUTICAL COMPOSITION FOR VAGINAL ADMINISTRATION |
| CN111759840B (zh) * | 2020-07-20 | 2021-05-11 | 温州市人民医院 | 一种防治心肌缺血的药物组合物及其制备方法和用途 |
| CN112190541A (zh) * | 2020-09-27 | 2021-01-08 | 安婕妤化妆品科技股份有限公司 | 一种私密护理凝胶产品 |
| CN112245657B (zh) * | 2020-10-19 | 2022-07-01 | 合肥中科智远生物科技有限公司 | 一种低放热抗菌骨水泥及其制备方法与应用 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5663208A (en) * | 1991-03-01 | 1997-09-02 | Warner-Lambert Company | Antifungal wound healing compositions and methods for preparing and using same |
| JPH09507073A (ja) * | 1993-12-23 | 1997-07-15 | ザ、プロクター、エンド、ギャンブル、カンパニー | 抗菌ふきとり組成物 |
| GB9610359D0 (en) * | 1996-05-17 | 1996-07-24 | Edko Trading Representation | Pharmaceutical compositions |
| US20030073646A1 (en) * | 1997-01-22 | 2003-04-17 | Marton Milankovits | Pharmaceutical compositions primarily for the treatment of genitourinary infections |
| US6416779B1 (en) * | 1997-06-11 | 2002-07-09 | Umd, Inc. | Device and method for intravaginal or transvaginal treatment of fungal, bacterial, viral or parasitic infections |
| FR2777783A1 (fr) * | 1998-04-24 | 1999-10-29 | Innothera Lab Sa | Association pharmaceutique d'imidazoles pour le traitement local des vulvo-vaginites infectieuses et des vaginoses |
-
2004
- 2004-03-10 GB GBGB0405406.0A patent/GB0405406D0/en not_active Ceased
- 2004-09-17 TR TR2006/06411T patent/TR200606411T1/xx unknown
- 2004-09-17 WO PCT/GB2004/003972 patent/WO2005087270A1/en not_active Ceased
- 2004-09-17 BR BRPI0418623-0A patent/BRPI0418623A/pt not_active IP Right Cessation
- 2004-09-17 CN CNA2004800430095A patent/CN1960763A/zh active Pending
- 2004-09-17 PL PL380815A patent/PL380815A1/pl not_active Application Discontinuation
- 2004-09-17 EA EA200601647A patent/EA011952B1/ru not_active IP Right Cessation
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4167964A4 (en) * | 2020-06-18 | 2024-07-17 | National Medical Supply, LLC | Vaginal gel |
Also Published As
| Publication number | Publication date |
|---|---|
| EA200601647A1 (ru) | 2007-02-27 |
| CN1960763A (zh) | 2007-05-09 |
| TR200606411T1 (tr) | 2007-01-22 |
| PL380815A1 (pl) | 2007-03-19 |
| GB0405406D0 (en) | 2004-04-21 |
| EA011952B1 (ru) | 2009-06-30 |
| WO2005087270A1 (en) | 2005-09-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI0418623A (pt) | composição farmacêutica, e, embalagem | |
| BRPI0615860B8 (pt) | composição farmacêutica de liberação prolongada monolítica sólida | |
| MXPA04001763A (es) | Descongestionantes en aerosol para el tratamiento de sinusitis. | |
| AR050838A1 (es) | Formulacion farmaceutica. para el tratamiento de una infeccion optica | |
| AR030068A1 (es) | Composiciones farmaceuticas para el tratamiento de condiciones dolorosas, inflamatorias y ulcerosas de superficies epiteliales humedas como por ejemplo mucositis, estomatitis y sindrome de behcet | |
| WO2003086408A8 (en) | Use of a2a adenosine receptor agonists for the treatment of inflammatory diseases | |
| ATE293995T1 (de) | Pharmazeutische zusammensetzungen, die wirkstoffabsorptionsfördernde verbindungen enthalten | |
| MX9505182A (es) | Composicion terapeutica para aplicacion topica, que contiene un antagonista de la substancia p. | |
| PT1401501E (pt) | Composicoes farmaceuticas orais com libertacao modificada do ingrediente activo | |
| BR9808581A (pt) | Estabilização de benzimidazóis sensìveis a ácido com combinações de aminoácido/ciclodextrina | |
| MX2009005307A (es) | Nuevas composiciones bajo la forma de ungüento libre de vaselina, que comprenden un derivado de vitamina d y eventualmente un anti-inflamatorio esteroide. | |
| SG147450A1 (en) | Sustained release pharmaceutical compositions comprising aplindore and derivatives thereof | |
| MX2023002671A (es) | Formulaciones agradables. | |
| BR0210595A (pt) | Regime de dosagem e composição farmacêutica para contracepção de emergência | |
| WO2007131253A3 (de) | Verwendung von kombinationspräparaten, umfassend antimykotika | |
| CO5580787A2 (es) | Metodos novedosos para el tratamiento de infecciones micoticas y bacterianas locales | |
| BRPI0415053B8 (pt) | inibidor de glicoproteína-p, método para preparar o mesmo e composição farmacêutica que compreende o mesmo | |
| BRPI0414305A (pt) | sistema de liberação de drogas por via oral | |
| DK1414467T3 (da) | Topisk behandling af mastalgi | |
| AR036357A1 (es) | Composicion de gel endoparasiticida, un metodo para su preparacion y el uso de dicha composición para la manufactura de un medicamento. | |
| MA33563B1 (fr) | 5-(3,4-dichloro-phényl)-n-(2-hydroxy-cyclohexyl)-6-(2,2,2-trifluoro-éthoxy)-nicotinamide et ses sels utilisés comme agents augmentant le cholestérol hdl | |
| BRPI0411702A (pt) | uso de ácido hialurÈnico para preparar composições para o tratamento de aftas da cavidade oral | |
| BR0209155A (pt) | Tablete farmacêutico tendo um teor de api elevado | |
| BR0206819A (pt) | Uso de inibidores de il-18 para o tratamento e/ou para a prevenção de doença cardìaca | |
| AR038858A1 (es) | Combinacion |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B06F | Objections, documents and/or translations needed after an examination request according art. 34 industrial property law | ||
| B25D | Requested change of name of applicant approved |
Owner name: EDKO PAZARLAMA TANITIM LIMITED SIRKETI (TR) Free format text: NOME ALTERADO DE: EDKO TRADING AND REPRESENTATION CO. LTD. |
|
| B08F | Application fees: dismissal - article 86 of industrial property law |
Free format text: REFERENTE A 9A ANUIDADE. |
|
| B08K | Lapse as no evidence of payment of the annual fee has been furnished to inpi (acc. art. 87) |
Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2260 DE 29/04/2014. |